The relationship between "on-treatment" low platelet reactivity and longitudinal risks of major bleeding dual antiplatelet therapy following acute coronary ...
Nov 4, 2016 · Although P2Y12 inhibitors have been shown to reduce ischemic events, there has been a consistent signal of increased bleeding with DAPT ...
The relationship between “on‐treatment” low platelet reactivity and longitudinal risks of major bleeding dual antiplatelet therapy following acute coronary ...
The relationship between "on-treatment" low platelet reactivity and longitudinal risks of major bleeding dual antiplatelet therapy following acute coronary ...
People also ask
What is an adverse effect of dual antiplatelet therapy?
Is DAPT therapy associated with bleeding risk?
Is longer duration of DAPT associated with increased bleeding risks?
What is a safe platelet count for dual antiplatelet therapy?
Not surprisingly, dual nonresponsiveness to antiplatelet treatment has been shown to increase the risk for cardiovascular events. 19, 30 Current literature ...
Dual platelet inhibition significantly reduces recurrent ischaemic events after non-ST-segment elevation acute coronary syndrome (NSTE ACS)1,2.
Mar 15, 2021 · Among 2289 medically managed patients, dual antiplatelet therapy (DAPT) use at discharge was greater in NSTEMI than in UA patients (81.8% vs ...
Mar 20, 2018 · Dual antiplatelet therapy (DAPT) with aspirin and a P2Y 12 -receptor antagonist plays a critical role in secondary prevention after an acute coronary syndrome ...
Nov 4, 2012 · First, we demonstrated no significant independent association between both PRU values and high platelet reactivity cut points with ischemic ...
In this updated consensus document, we review the available evidence addressing the relation of platelet reactivity to thrombotic and bleeding events.